Details about Aidan Hollis
Access statistics for papers by Aidan Hollis.
Last updated 2022-01-26. Update your information in the RePEc Author Service.
Short-id: pho163
Jump to Journal Articles
Working Papers
2010
- Generic drug pricing in Canada: components of the value-chain
Working Papers, Department of Economics, University of Calgary
- New Approaches to Rewarding Pharmaceutical Innovation
Levine's Bibliography, UCLA Department of Economics View citations (3)
2008
- Privacy, Driving Data and Automobile Insurance: An Economic Analysis
Working Papers, Department of Economics, University of Calgary
Also in MPRA Paper, University Library of Munich, Germany (2007) View citations (4)
1997
- Complementarity, Competition and Institutional Development: The Irish Loan Funds through Three Centuries
Economic History, University Library of Munich, Germany View citations (4)
- Microcredit in Pre-Famine Ireland
Economic History, University Library of Munich, Germany View citations (3)
See also Journal Article in Explorations in Economic History (1998)
1996
- A Contractual Approach to the Gray Market
Working Papers, University of Toronto, Department of Economics View citations (1)
See also Journal Article in International Review of Law and Economics (1999)
- Exclusivity Restrictions in Markets with Adverse Selection: The Case of Extended Warranties
Working Papers, University of Toronto, Department of Economics
- Subsidizing the Competition
Working Papers, University of Toronto, Department of Economics
- The Evolution of A Microcredit Institution: The Irish Loan Funds, 1720 - 1920
Working Papers, University of Toronto, Department of Economics View citations (1)
Journal Articles
2021
- The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications
Health Economics, 2021, 30, (5), 1139-1151
2020
- Patient income and health innovation
Health Economics, 2020, 29, (12), 1795-1803 View citations (1)
2019
- How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
Health Policy, 2019, 123, (12), 1251-1258
2018
- Making Sure Orphan Drugs Don’t Get Left Behind
SPP Communique, 2018, 10, (6)
2016
- Sustainable Financing of Innovative Therapies: A Review of Approaches
PharmacoEconomics, 2016, 34, (10), 971-980 View citations (1)
2015
- Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics
International Journal of the Economics of Business, 2015, 22, (2), 201-217 View citations (3)
- Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals
Health Economics, 2015, 24, (8), 966-977 View citations (4)
2014
- The path of least resistance: Paying for antibiotics in non-human uses
Health Policy, 2014, 118, (2), 264-270 View citations (2)
2010
- The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers
Energy Policy, 2010, 38, (7), 3837-3846 View citations (34)
2009
- Generic Drug Pricing and Procurement: A Policy for Alberta
SPP Research Papers, 2009, 2, (1) View citations (2)
2007
- Preliminary Injunctions and Damage Rules in Patent Law
Journal of Economics & Management Strategy, 2007, 16, (2), 385-405 View citations (8)
- The Role of Local Depositors in Controlling Expenses in Small‐Scale Financial Intermediation: An Empirical Analysis
Economica, 2007, 74, (296), 713-735 View citations (5)
2005
- Governance of electricity transmission systems
Energy Economics, 2005, 27, (2), 237-255 View citations (9)
- How do Brands’ “Own Generics” Affect Pharmaceutical Prices?
Review of Industrial Organization, 2005, 27, (4), 329-350 View citations (8)
2004
- A National Formulary for Canada
Canadian Public Policy, 2004, 30, (4), 445-452
- Competition policy in open economies
International Economic Journal, 2004, 18, (2), 179-193 View citations (3)
- Microfinance and Famine: The Irish Loan Funds during the Great Famine
World Development, 2004, 32, (9), 1509-1523 View citations (6)
2003
- Industrial Concentration, Output, and Trade: An Empirical Exploration
Review of Industrial Organization, 2003, 22, (2), 103-119 View citations (7)
- The Anti-Competitive Effects of Brand-Controlled "Pseudo- Generics" in the Canadian Pharmaceutical Market
Canadian Public Policy, 2003, 29, (1), 21-31 View citations (14)
2002
- Strategic Implications of Learning by Doing
International Journal of the Economics of Business, 2002, 9, (2), 157-174 View citations (4)
- The importance of being first: evidence from Canadian generic pharmaceuticals
Health Economics, 2002, 11, (8), 723-734 View citations (23)
2001
- Co-authorship and the output of academic economists
Labour Economics, 2001, 8, (4), 503-530 View citations (111)
- The life-cycle of a microfinance institution: the Irish loan funds
Journal of Economic Behavior & Organization, 2001, 46, (3), 291-311 View citations (11)
1999
- A contractual approach to the gray market
International Review of Law and Economics, 1999, 19, (1), 1-21 View citations (22)
See also Working Paper (1996)
1998
- Microcredit in Prefamine Ireland
Explorations in Economic History, 1998, 35, (4), 347-380 View citations (13)
See also Working Paper (1997)
- Microcredit: What can we learn from the past?
World Development, 1998, 26, (10), 1875-1891 View citations (42)
|
The links between different versions of a paper are constructed automatically by matching on the titles.
Please contact if a link is incorrect.
Use this form
to add links between versions where the titles do not match.
|